Date: 2014-07-01
Type of information: R&D agreement
Compound: ImmunTraCkeR® and ImmunIG® tests
Company: ImmunID (France) Singapore Immunology Network (SIgN) (Singapore)
Therapeutic area: Diagnostic
Type agreement: R&D collaboration
Action mechanism: companion diagnostic. ImmunTraCkeR® is an immune companion diagnostic test for new immunotherapies. This molecular test uses a multi-N-Plex® Polymerase Chain Reaction technology to detect V-J rearrangements of the T cell receptor (TCR) at the genomic DNA level. This molecular test can be used to characterize the human T cell repertoire diversity richness (beta chain of the T cell receptor, TCR) in a Peripheral Blood Mononuclear Cell sample isolated from whole blood.
Disease: undisclosed
Details: * On July 1st, 2014, ImmunID, a French Immune Molecular Diagnostics company, announced an agreement with the Singapore Immunology Network (SIgN), a research institute under the Agency of Science, Technology and Research (A*STAR), Singapore. Under the agreement, ImmunID will use its proprietary ImmunTraCkeR® and ImmunIG® tests to evaluate T and B immune repertoire diversity in the blood of patients enrolled in a SIgN-led clinical trial. The project will last for 2 years and include 180 subjects. The indication and therapeutic intervention studied in SIgN’s clinical trial were not disclosed.
Financial terms:
Latest news:
